Yang Joanna C, Terezakis Stephanie A, Dunkel Ira J, Gilheeney Stephen W, Wolden Suzanne L
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York.
Department of Radiation Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland.
Pediatr Blood Cancer. 2016 Apr;63(4):646-51. doi: 10.1002/pbc.25867. Epub 2015 Dec 24.
We sought to assess patterns of failure in pediatric patients with intracranial germ cell tumors (GCT) treated with intensity-modulated radiation therapy with dose painting (DP-IMRT).
Between July 2007 and October 2013, 11 patients with localized GCT-five germinomas and six nongerminoma GCT (NGGCT)-received definitive treatment with DP-IMRT. Three representative patients were selected for replanning with (i) whole ventricular irradiation (WVI) with opposed lateral beams plus IMRT to the primary tumor and (ii) sequential IMRT. These plans were compared to the patients' original DP-IMRT plans for dosimetric analyses.
Four patients with germinoma received radiation therapy alone: 45 Gy in 1.8 Gy fractions to the primary tumor and 25 Gy in 1.0 Gy fractions to whole ventricles using a dose-painting plan. One patient with germinoma received a reduced dose of 30.6 Gy to the primary tumor after neoadjuvant chemotherapy. Patients with NGGCT (n = 6) underwent multimodality treatment including chemotherapy (n = 6) and surgery (n = 3). These patients received 54 Gy to the primary tumor and 32.4-36 Gy to the whole ventricles. Dosimetric analyses showed DP-IMRT delivered decreased mean dose to whole brain, temporal lobes, hippocampi, cochleae, and optic nerves. With median follow-up of 4 years, 3-year failure-free survival was 100% for patients with germinoma and 67% for patients with NGGCT. One patient with a pineal NGGCT experienced a local recurrence within the high dose-volume while another experienced an isolated biochemical failure.
DP-IMRT is dosimetrically superior to standard IMRT techniques for sparing of normal tissues. Disease control in this small series appears at least comparable to published results.
我们试图评估采用剂量调强放疗(DP-IMRT)治疗的小儿颅内生殖细胞瘤(GCT)患者的失败模式。
2007年7月至2013年10月期间,11例局限性GCT患者(5例生殖细胞瘤和6例非生殖细胞瘤性GCT[NGGCT])接受了DP-IMRT根治性治疗。选取3例有代表性的患者进行重新计划,分别采用(i)双侧对穿野全脑室照射(WVI)联合对原发肿瘤的IMRT以及(ii)序贯IMRT。将这些计划与患者最初的DP-IMRT计划进行剂量学分析比较。
4例生殖细胞瘤患者仅接受放疗:采用剂量调强计划,原发肿瘤给予45 Gy,分1.8 Gy每次,全脑室给予25 Gy,分1.0 Gy每次。1例生殖细胞瘤患者在新辅助化疗后原发肿瘤接受了30.6 Gy的减量照射。NGGCT患者(n = 6)接受了多模式治疗,包括化疗(n = 6)和手术(n = 3)。这些患者原发肿瘤接受54 Gy照射,全脑室接受32.4 - 36 Gy照射。剂量学分析显示,DP-IMRT降低了全脑、颞叶、海马、耳蜗和视神经的平均剂量。中位随访4年,生殖细胞瘤患者的3年无失败生存率为100%,NGGCT患者为67%。1例松果体区NGGCT患者在高剂量区出现局部复发,另1例出现孤立的生化复发。
在保护正常组织方面,DP-IMRT在剂量学上优于标准IMRT技术。该小样本系列中的疾病控制情况似乎至少与已发表的结果相当。